title: Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy.
abstract: Ten patients with newly diagnosed haematological malignancy were given ofloxacin, 400 mg daily orally, for antibacterial prophylaxis during neutropenia. Before cytotoxic chemotherapy was given, and on three occasions between days 2-3, 5-7 and 8-10 afterwards, blood samples were taken before and 1, 2, 3, 4, 6 and 10 h after administration of ofloxacin. Serum ofloxacin concentrations were measured by HPLC. Mean (range) pharmacokinetic parameters before chemotherapy were: Cmax, 6.1 (2.7-9.1) mg/L; AUC0-2, 7.5 (1.9-11.6) mg.h/L. On days 2-3 post-chemotherapy the values were reduced to: Cmax, 5.0 (3.6-7.3) mg/L; AUC0-2, 5.8 (1.9-7.8) mg.h/L. On days 5-7 the values were: Cmax, 6.1 (4.0-10.4) mg/L; AUC0-2, 8.5 (0.8-16.8) mg.h/L, and by days 8-10 the values were: Cmax, 6.4 (3.3-12.5) mg/L; AUC0-2, 8.6 (0.8-23.1) mg.h/L. There was a statistically significant difference between Cmax pre- and Cmax two to three days post-chemotherapy (paired t-test, P = 0.05). These changes are similar to those previously reported with ciprofloxacin but less marked.
authors.affiliation: Department of Medical Microbiology, Southmead Hospital, Bristol, UK.
authors.forename: N M
authors.initials: NM
authors.lastname: Brown
authors.forename: L O
authors.initials: LO
authors.lastname: White
authors.forename: E L
authors.initials: EL
authors.lastname: Blundell
authors.forename: S R
authors.initials: SR
authors.lastname: Chown
authors.forename: R R
authors.initials: RR
authors.lastname: Slade
authors.forename: A P
authors.initials: AP
authors.lastname: MacGowan
authors.forename: D S
authors.initials: DS
authors.lastname: Reeves
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D007938:Leukemia / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000382:microbiology / Q000517:prevention & control; D015242:Ofloxacin / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
chemical_list: D000970:Antineoplastic Agents; D015242:Ofloxacin